Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2

Biochemical Pharmacology

Volumn 86, Issue 4, 2013, Pages 469-475

  Castro, M M ^a   Fuah, J ^a   Ali, M ^a   Sung, M ^a   Schulz, J ^a   Kondo, M Y ^a   Fan, X ^a   Holt, A ^a   Schulz, R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Caspase inhibitors; Caspases; Hypoxia reoxygenation; Matrix metalloproteinase 2; Troponin I

Indexed keywords

2 ACETAMIDO 4 METHYL N [4 METHYL 1 [(4 METHYLSULFANYL 1 OXOBUTAN 2 YL) AMINO] 1 OXOPENTAN 2 YL]PENTANAMIDE; 3 [[2 [[2 [[2 ACETAMIDO 3 (4 HYDROXYPHENYL)PROPANOYL]AMINO] 3 METHYLBUTANOYL]AMINO]PROPANOYL]AMINO] 5 CHLORO 4 OXOPENTANOIC ACID; 4 [(2 ACETAMIDO 3 CARBOXYPROPANOYL)AMINO] 5 [[1 [(1 CARBOXY 3 OXOPROPAN 2 YL)AMINO] 3 METHYL 1 OXOBUTAN 2 YL]AMINO] 5 OXOPENTANOIC ACID; 4 [(2 ACETAMIDO 4 METHYLPENTANOYL)AMINO] 5 [[1 [(1 CARBOXY 4 CHLORO 3 OXOBUTAN2 YL)AMINO] 3 (1H IMIDAZOL 5 YL) 1 OXOPROPAN 2 YL]AMINO] 5 OXOPENTANOIC ACID; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; 5 FLUORO 3 [[2 [[3 METHYL 2 (PHENYLMETHOXYCARBONYLAMINO)BUTANOYL]AMINO]PROPANOYL]AMINO] 4 OXOPENTANOIC ACID; ARP 100; CASPASE INHIBITOR; ENZYME INHIBITOR; GELATINASE A; METHYL 5 [[1 [(5 FLUORO 1 METHOXY 1, 4 DIOXOPENTAN 3 YL)AMINO] 3 HYDROXY 1 OXOBUTAN 2 YL]AMINO] 4 [[3 METHYL 2 (PHENYLMETHOXYCARBONYLAMINO)PENTANOYL]AMINO] 5 OXOPENTANOATE; N HYDROXY 2 [(4 PHENYLPHENYL)SULFONYL PROPAN 2 YLOXYAMINO]ACETAMIDE; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HEART MUSCLE CELL; HEART PROTECTION; IC 50; IN VITRO STUDY; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; RAT; REOXYGENATION; WESTERN BLOTTING;

EID: 84884904867     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.06.003     Document Type: Article

References (39)

1. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62. (Pubitemid 34633925)
2. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42.
3. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011;64:567-72.
4. Ali MA, Chow AK, Kandasamy AD, Fan X, West LJ, Crawford BD, et al. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol 2012;227:3397-404.
5. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, et al. Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009;77:826-34.
6. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53:165-74. (Pubitemid 34020777)
7. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007;43:429-36. (Pubitemid 47451426)
8. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003;57:426-33. (Pubitemid 36144221)
9. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
10. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia- reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005;112:544-52. (Pubitemid 41060795)
11. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010;122:2039-47.
12. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115:2665-72. (Pubitemid 41434390)
13. Rupinder SK, Gurpreet AK, Manjeet S. Cell suicide and caspases. Vascul Pharmacol 2007;46:383-93. (Pubitemid 46552286)
14. Crawford ED, Wells JA. Caspase substrates and cellular remodeling. Annu Rev Biochem 2011;80:1055-87.
15. Kovacs P, Bak I, Szendrei L, Vecsernyes M, Varga E, Blasig IE, et al. Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/reperfused rat hearts. Naunyn Schmiedebergs Arch Pharmacol 2001;364:501-7. (Pubitemid 33145089)
16. Vanden Hoek TL, Qin Y, Wojcik K, Li CQ, Shao ZH, Anderson T, et al. Reperfusion, not simulated ischemia, initiates intrinsic apoptosis injury in chick cardiomyocytes. Am J Physiol Heart Circ Physiol 2003;284:H1141-50.
17. de Moissac D, Gurevich RM, Zheng H, Singal PK, Kirshenbaum LA. Caspase activation and mitochondrial cytochrome C release during hypoxia-mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol 2000;32:53-63. (Pubitemid 30064304)
18. Yarbrough WM, Mukherjee R, Squires CE, Reese ES, Leiser JS, Stroud RE, et al. Caspase inhibition attenuates contractile dysfunction following cardioplegic arrest and rewarming in the setting of left ventricular failure. J Cardiovasc Pharmacol 2004;44:645-50. (Pubitemid 39587424)
19. Ruetten H, Badorff C, Ihling C, Zeiher AM, Dimmeler S. Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis- inhibitory effects. J Am Coll Cardiol 2001;38:2063-70. (Pubitemid 33116585)
20. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A 2002;99:6252-6 (Pubitemid 34493298)
21. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1847-60. (Pubitemid 46572408)
22. Nicolescu AC, Holt A, Kandasamy AD, Pacher P, Schulz R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun 2009;387:646-50.
23. Hariya A, Takazawa K, Yamamoto T, Amano A. ONO-4817, a novel matrix metalloproteinase inhibitor, attenuates allograft vasculopathy in a rat cardiac transplant. J Heart Lung Transplant 2004;23:1163-9. (Pubitemid 39346232)
24. Shirahane K, Yamaguchi K, Koga K, Watanabe M, Kuroki S, Tanaka M. Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817. Surgery 2006;139:653-64.
25. Yamada A, Uegaki A, Nakamura T, Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 2000;49:144-6. (Pubitemid 30262710)
26. Ali MA, Stepanko A, Fan X, Holt A, Schulz R. Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochem Biophys Res Commun 2012;423:1-5.
27. Rossello A, Nuti E, Orlandini E, Carelli P, Rapposelli S, Macchia M, et al. New Narylsulfonyl- N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). Bioorg Med Chem 2004;12:2441-50. (Pubitemid 38471726)
28. Tuccinardi T,MartinelliA, Nuti E, Carelli P, Balzano F, Uccello-Barretta G, et al. Amber force field implementation, molecular modelling study, synthesis and MMP-1/ MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N- isopropoxybiphenyl-4- ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem 2006;14:4260-76.
29. Yue TL, Wang C, Romanic AM, Kikly K, Keller P, DeWolf Jr WE, et al. Staurosporine- induced apoptosis in cardiomyocytes: a potential role of caspase-3. J Mol Cell Cardiol 1998;30:495-507. (Pubitemid 28132729)
30. Neviere R, Hassoun SM, Decoster B, Bouazza Y, Montaigne D, Marechal X, et al. Caspase-dependent protein phosphatase 2A activation contributes to endotoxin- induced cardiomyocyte contractile dysfunction. Crit Care Med 2010;38:2031-6.
31. Hu CP, Dandapat A, Liu Y, Hermonat PL, Mehta JL. Blockade of hypoxiareoxygenation- mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes. Am J Physiol Heart Circ Physiol 2007;293:H1833-38. (Pubitemid 47367232)
32. Bian Y, Sun M, Silver M, Ho KK, Marchionni MA, Caggiano AO, et al. Neuregulin- 1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol 2009;297:H1974-83.
33. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, Pacher P. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 2004;11:505-8.
34. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 1999;442:117-21. (Pubitemid 29065390)
35. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-98. (Pubitemid 47064570)
36. Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ 2007;14:73-8. (Pubitemid 44911896)
37. Pereira NA, Song Z. Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem Biophys Res Commun 2008;377:873-7.
38. Muller I, Lamers MB, Ritchie AJ, Dominguez C, Munoz-Sanjuan I, Kiselyov A. Structure of human caspase-6 in complex with Z-VAD-FMK: new peptide binding mode observed for the non-canonical caspase conformation. Bioorg Med Chem Lett 2011;21:5244-7.
39. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease- 13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-91. (Pubitemid 47529503)